Expression and prognostic significance of VEGF and mTOR pathway proteins in metastatic renal cell carcinoma patients: a prognostic immunohistochemical profile for kidney cancer patients

Liontos Michalis; Trigka Eleni-Andriana; Korkolopoulou Penelope; Tzannis Kimon; Lainakis Giorgos; Koutsoukos Konstantinos; Kostouros Efthymios; Lykka Maria; Papandreou Christos N.; Karavasilis Vassilis; Christodoulou Christos; Papatsoris Athanasios; Skolarikos Andreas; Varkarakis Ioannis; Adamakis Ioannis; Alamanis Christos; Stravodimos Konstantinos; Mitropoulos Dionysios; Deliveliotis Charalambos; Constantinidis Constantinos A.; Saetta Angelica; Patsouris Efstratios; Dimopoulos Meletios I.; Bamias Aristotelis

首页> 外文期刊>World journal of urology >Expression and prognostic significance of VEGF and mTOR pathway proteins in metastatic renal cell carcinoma patients: a prognostic immunohistochemical profile for kidney cancer patients

【24h】

Expression and prognostic significance of VEGF and mTOR pathway proteins in metastatic renal cell carcinoma patients: a prognostic immunohistochemical profile for kidney cancer patients

机译：VEGF和MTOR途径蛋白在转移性肾细胞癌患者中的表达及预后意义：肾癌患者的预后免疫组织化学曲线

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

To identify prognostic molecular profiles in patients with mRCC treated with sunitinib, we performed immunohistochemical analysis for VEGF and PI3K/Akt/mTOR pathway components.

机译：为了鉴定用Sunitinib治疗MRCC患者的预后分子曲线，我们对VEGF和PI3K / AKT / MTOR途径组分进行了免疫组化分析。

著录项

来源
《World journal of urology》 |2017年第3期|共9页
作者
Liontos Michalis; Trigka Eleni-Andriana; Korkolopoulou Penelope; Tzannis Kimon; Lainakis Giorgos; Koutsoukos Konstantinos; Kostouros Efthymios; Lykka Maria; Papandreou Christos N.; Karavasilis Vassilis; Christodoulou Christos; Papatsoris Athanasios; Skolarikos Andreas; Varkarakis Ioannis; Adamakis Ioannis; Alamanis Christos; Stravodimos Konstantinos; Mitropoulos Dionysios; Deliveliotis Charalambos; Constantinidis Constantinos A.; Saetta Angelica; Patsouris Efstratios; Dimopoulos Meletios I.; Bamias Aristotelis;
展开▼
作者单位

Univ Athens Sch Med Alexandra Hosp Oncol Unit Dept Clin Therapeut 80 V Sofias Ave Athens 11528;

Univ Athens Sch Med Laiko Hosp Dept Pathol 1 Athens Greece;

Univ Athens Sch Med Laiko Hosp Dept Pathol 1 Athens Greece;

Univ Athens Sch Med Alexandra Hosp Oncol Unit Dept Clin Therapeut 80 V Sofias Ave Athens 11528;

Univ Athens Sch Med Alexandra Hosp Oncol Unit Dept Clin Therapeut 80 V Sofias Ave Athens 11528;

Univ Athens Sch Med Alexandra Hosp Oncol Unit Dept Clin Therapeut 80 V Sofias Ave Athens 11528;

Univ Athens Sch Med Alexandra Hosp Oncol Unit Dept Clin Therapeut 80 V Sofias Ave Athens 11528;

Univ Athens Sch Med Alexandra Hosp Oncol Unit Dept Clin Therapeut 80 V Sofias Ave Athens 11528;

Univ Thessaly Sch Hlth Sci Fac Med Dept Med Oncol Larisa Greece;

Aristotle Univ Thessaloniki Sch Med Papageorgiou Hosp Dept Med Oncol Thessaloniki Greece;

Metropolitan Hosp Dept Med Oncol 2 Piraeus Greece;

Univ Athens Sch Med Sismanoglio Hosp Dept Urol 2 Athens Greece;

Univ Athens Sch Med Sismanoglio Hosp Dept Urol 2 Athens Greece;

Univ Athens Sch Med Sismanoglio Hosp Dept Urol 2 Athens Greece;

Univ Athens Sch Med Laiko Hosp Dept Urol 1 Athens Greece;

Univ Athens Sch Med Laiko Hosp Dept Urol 1 Athens Greece;

Hellen GenitoUrinary Canc Grp Athens Greece;

Hellen GenitoUrinary Canc Grp Athens Greece;

Univ Athens Sch Med Sismanoglio Hosp Dept Urol 2 Athens Greece;

Hellen GenitoUrinary Canc Grp Athens Greece;

Univ Athens Sch Med Laiko Hosp Dept Pathol 1 Athens Greece;

Univ Athens Sch Med Laiko Hosp Dept Pathol 1 Athens Greece;

Univ Athens Sch Med Alexandra Hosp Oncol Unit Dept Clin Therapeut 80 V Sofias Ave Athens 11528;

Univ Athens Sch Med Alexandra Hosp Oncol Unit Dept Clin Therapeut 80 V Sofias Ave Athens 11528;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类泌尿科学（泌尿生殖系疾病）;
关键词
mRCC; Sunitinib; VEGF; mTOR;

机译：MRCC;孙尼替尼;VEGF;MTOR;

相似文献

外文文献
中文文献
专利

1. Expression and prognostic significance of VEGF and mTOR pathway proteins in metastatic renal cell carcinoma patients: a prognostic immunohistochemical profile for kidney cancer patients [J] . Liontos Michalis, Trigka Eleni-Andriana, Korkolopoulou Penelope, World journal of urology . 2017,第3期

机译：VEGF和MTOR途径蛋白在转移性肾细胞癌患者中的表达及预后意义：肾癌患者的预后免疫组织化学曲线
2. Re: Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas [J] . TanejaS.S. The Journal of Urology . 2012,第2期

机译：回复：mTOR和缺氧诱导的通路成员在原发性和转移性透明细胞肾细胞癌中的免疫表达状态和预后价值
3. Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas. [J] . Schultz L, Chaux A, Albadine R, American Journal of Surgical Pathology . 2011,第10期

机译：mTOR和缺氧诱导的通路成员在原发性和转移性透明细胞肾细胞癌中的免疫表达状态和预后价值。
4. Prognostic Significance of COX-2 and VEGF in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy [C] . Gang-Ping WANG, Xue WANG, Zhao-Jun DING, International Conference on Biological Sciences and Technology . 2016

机译：Cox-2和VEGF在接受新辅助化疗的乳腺癌患者中的预后意义
5. Analysis of prognostic factors for the development of metastases and survival in renal cell carcinoma patients [D] . Cheng, Jed-Sian 2008

机译：肾细胞癌患者转移和存活的预后因素分析
6. Prognostic significance of ST6GalNAc-1 expression in patients with non-metastatic clear cell renal cell carcinoma [O] . Qi Bai, Li Liu, Wei Xi, 2018

机译：ST6GalNAc-1表达在非转移性透明细胞肾细胞癌患者中的预后意义
7. Prognostic factors of the therapeutic efficacy of mTOR and VEGFR inhibitors in patients with metastatic renal cell carcinoma [O] . E. A. Voroshilova, D. A. Nosov, A. V. Karpukhin, 2015

机译：MTOR和VEGFR抑制剂在转移性肾细胞癌患者中的治疗疗效的预后因素

Expression and prognostic significance of VEGF and mTOR pathway proteins in metastatic renal cell carcinoma patients: a prognostic immunohistochemical profile for kidney cancer patients

摘要

著录项

相似文献

相关主题

期刊订阅